跳至主要内容
临床试验/NCT05960097
NCT05960097已完成2 期

A Phase 2 Randomized, Active-controlled, Observer-blind Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Booster Dose of Investigational COVID-19 mRNA Vaccines in Healthy Adults Who Previously Received a Complete Primary Vaccination Series With or Without Booster Dose(s)

GlaxoSmithKline1 个研究点 分布在 1 个国家目标入组 692 人开始时间: 2023年8月1日最近更新:
干预措施

试验速览

阶段
2 期
状态
已完成
入组人数
692
试验地点
1
主要终点
Part A: Geometric Mean Titer (GMT) of Serum Neutralization Titers Against Pseudovirus Bearing SARS-CoV-2 Strain XX Spike Protein

研究概览

简要总结

The purpose of Part A of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults. The study will compare the investigational vaccines to control vaccine.

The purpose of Part B of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults. The study will compare the investigational vaccine under three different storage conditions.

详细描述

Part A:

This Phase 2 study's Part A evaluates the safety, reactogenicity, and immunogenicity of two candidate vaccines - the bivalent CV0701 and the monovalent CV0601 - in healthy adults who have received a full primary vaccination series (with or without booster doses). By including these candidates, the study will assess whether immune interference occurs between the XY spike protein and the XX spike protein antigens in the bivalent vaccine compared with the XX spike protein antigen in the monovalent vaccine. In Part A, both CV0701 and CV0601 will be compared to the Control Vaccine (that serve as a standard of care control) using a randomized, observer-blinded design.

Part B:

The purpose of Part B is to evaluate the safety and Day 29 immunogenicity of CV0801 under three storage conditions:

  • Condition 1: Baseline/control
  • Condition 2: Intermediate storage
  • Condition 3: Maximum storage

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Investigator, Outcomes Assessor)

盲法说明

This is an observer-blind study.

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Part A: CV0701 mRNA COVID-19 Vaccine (High dose)

Experimental

Participants received one dose of the CV0701 mRNA COVID-19 vaccine in the high-dose formulation on Day 1.

干预措施: CV0701 mRNA COVID-19 Vaccine (High dose) (Biological)

Part A: CV0601 mRNA COVID-19 vaccine

Experimental

Participants received one dose of the CV0601 mRNA COVID-19 vaccine on Day 1.

干预措施: CV0601 mRNA COVID-19 Vaccine (Biological)

Part A: CV0701 mRNA COVID-19 Vaccine (Low dose)

Experimental

Participants received one dose of the CV0701 mRNA COVID-19 vaccine in the low-dose formulation on Day 1.

干预措施: CV0701 mRNA COVID-19 Vaccine (Low dose) (Biological)

Part A: CV0701 mRNA COVID-19 Vaccine (Medium dose)

Experimental

Participants received one dose of the CV0701 mRNA COVID-19 vaccine in the medium-dose formulation on Day 1.

干预措施: CV0701 mRNA COVID-19 Vaccine (Medium dose) (Biological)

Part A: Control Vaccine

Active Comparator

Participants received one dose of the control vaccine at Day 1.

干预措施: Control vaccine (Biological)

Part B: CV0801 mRNA COVID-19 vaccine (Maximum storage condition)

Experimental

Participants received one dose of the CV0801 mRNA COVID-19 vaccine on Day 1 under Maximum storage condition.

干预措施: CV0801 mRNA COVID-19 Vaccine (Biological)

Part B: CV0801 mRNA COVID-19 vaccine (Intermediate storage condition)

Experimental

Participants received one dose of the CV0801 mRNA COVID-19 vaccine on Day 1 under Intermediate storage condition.

干预措施: CV0801 mRNA COVID-19 Vaccine (Biological)

Part B: CV0801 mRNA COVID-19 vaccine (Baseline-control storage condition)

Experimental

Participants received one dose of the CV0801 mRNA COVID-19 vaccine on Day 1 under Baseline-control storage condition.

干预措施: CV0801 mRNA COVID-19 Vaccine (Biological)

结局指标

主要结局

Part A: Geometric Mean Titer (GMT) of Serum Neutralization Titers Against Pseudovirus Bearing SARS-CoV-2 Strain XX Spike Protein

时间窗: At Day 29

Part A: GMT of Serum Neutralization Titers Against Pseudovirus Bearing SARS-CoV-2 Strain XY Spike Protein

时间窗: At Day 29

Part B: Number of Participants Reporting Any Solicited Administration Site AEs

时间窗: Day 1 to Day 7

Assessed solicited administration site events included injection site redness (erythema), pain, swelling and lymphadenopathy (defined as localized axillary, cervical or supraclavicular swelling or tenderness ipsilateral to the injection arm). Any = occurrence of the event regardless of intensity grade.

Part B: GMT of Serum Neutralization Titers Against Pseudovirus Bearing SARS-CoV-2 Strain XY Spike Protein

时间窗: At Day 29

Part A: Number of Participants Reporting Any Solicited Administration Site Adverse Events (AEs)

时间窗: Day 1 to Day 7

Assessed solicited administration site events included injection site redness (erythema), pain, swelling and lymphadenopathy (defined as localized axillary, cervical or supraclavicular swelling or tenderness ipsilateral to the injection arm). Any = occurrence of the event regardless of intensity grade.

Part A: Number of Participants Reporting Any Solicited Systemic AEs

时间窗: Day 1 to Day 7

Assessed solicited systemic events included fever, chills, headache, myalgia (muscle pain), arthralgia (joint pain), and fatigue (tiredness). Fever is defined as body temperature is higher than or equal to (\>=) 38ºC; preferred location for measuring the temperature is oral. Any = occurrence of the event regardless of intensity grade.

Part A: Number of Participants Reporting Any Unsolicited AEs

时间窗: Day 1 to Day 28

An unsolicited AE is an AE that is either not included in the list of solicited events or can be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs include both serious and nonserious AEs. Any = occurrence of the event regardless of intensity grade.

Part A: Number of Participants Reporting Any Medically Attended Adverse Events (MAAEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)

时间窗: Day 1 to Day 181

An SAE refers to any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or extends existing hospitalization, causes persistent or significant disability/incapacity, involves a congenital anomaly/birth defect in a participant's offspring, includes an abnormal pregnancy outcome, or occurs in any other situation per the investigator's judgement. An MAAE results in a visit to a medical professional, such as televisits, physician's office visits, urgent care visits, emergency rooms visits, or hospitalizations. AESIs are severe or non-severe predefined AEs of scientific and medical concern specific to the product/program. This study noted the following AESIs: potential immune-mediated disease (pIMDs), lab-confirmed moderate to severe COVID-19, myocarditis and pericarditis, anaphylaxis, or severe hypersensitivity within 24 hours post-intervention. "Any" indicates the occurrence of the event regardless of its intensity grade.

Part B: Number of Participants Reporting Any Solicited Systemic AEs

时间窗: Day 1 to Day 7

Assessed solicited systemic events included fever, chills, headache, myalgia (muscle pain), arthralgia (joint pain), and fatigue (tiredness). Fever is defined as body temperature \>= 38ºC; preferred location for measuring the temperature is oral. Any = occurrence of the event regardless of intensity grade.

Part B: Number of Participants Reporting Any Unsolicited AEs

时间窗: Day 1 to Day 28

An unsolicited AE is an AE that is either not included in the list of solicited events or can be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs include both serious and nonserious AEs. Any = occurrence of the event regardless of intensity grade.

Part B: Number of Participants Reporting Any MAAEs, SAEs and AESIs

时间窗: Day 1 to Day 181

次要结局

  • Part A: GMT of Serum Neutralization Titers Against Pseudovirus Bearing SARS-CoV-2 Strain XX Spike Protein(At Day 91 and Day 181)
  • Part A: GMT of Serum Neutralization Titers Against Pseudovirus Bearing SARS-CoV-2 Strain XY Spike Protein(At Day 91 and Day 181)
  • Part A: GMT of Serum Neutralization Titers Against Pseudovirus Bearing SARS-CoV-2 Strain XZ Spike Protein(At Day 29, Day 91 and Day 181)
  • Part A: Percentage of Participants With Seroresponse of Serum Neutralization Titers Against Pseudovirus Bearing SARS-CoV-2 Strain XX Spike Protein(At Day 29 compared to baseline (Day 1))
  • Part A: Percentage of Participants With Seroresponse of Serum Neutralization Titers Against Pseudovirus Bearing SARS-CoV-2 Strain XY Spike Protein(At Day 29 compared to baseline (Day 1))
  • Part A: Percentage of Participants With Seroresponse of Serum Neutralization Titers Against Pseudovirus Bearing SARS-CoV-2 Strain XZ Spike Protein(At Day 29 compared to baseline (Day 1))
  • Part A: Geometric Mean Increase (GMI) of Serum Neutralization Titers Against Pseudovirus Bearing SARS-CoV-2 Strain XX Spike Protein(At Day 29, Day 91 and Day 181 compared to baseline (Day 1))
  • Part A: GMI of Serum Neutralization Titers Against Pseudovirus Bearing SARS-CoV-2 Strain XY Spike Protein(At Day 29, Day 91 and Day 181 compared to baseline (Day 1))
  • Part A: GMI of Serum Neutralization Titers Against Pseudovirus Bearing SARS-CoV-2 Strain XZ Spike Protein(At Day 29, Day 91 and Day 181 compared to baseline (Day 1))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验